Upadacitinib for the treatment of psoriatic arthritis
Psoriatic arthritis is a chronic systemic inflammatory disease that presents with a variable clinical course and is typically associated with joint inflammation, together with cutaneous psoriasis. In recent decades, knowledge of the pathogenesis of psoriatic arthritis has advanced considerably and h...
Main Authors: | Diogo Fonseca, Miguel Nogueira, Tiago Torres |
---|---|
Format: | Article |
Language: | English |
Published: |
BioExcel Publishing Ltd
2023-02-01
|
Series: | Drugs in Context |
Subjects: | |
Online Access: | https://www.drugsincontext.com/upadacitinib-for-the-treatment-of-psoriatic-arthritis/ |
Similar Items
-
Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives
by: Ly K, et al.
Published: (2019-08-01) -
Conventional Synthetic Disease-Modifying Anti-rheumatic Drugs for Psoriatic Arthritis: Findings and Implications From a Patient Centered Longitudinal Study in Brazil
by: Ronaldo José Faria, et al.
Published: (2022-04-01) -
Access to high-cost medications for psoriatic arthritis in the National Health System in Brazil: the long path up to dispensation
by: Michael Ruberson Ribeiro da Silva, et al.
Published: (2019-11-01) -
Use of Apremilast to Achieve Psoriatic Arthritis Treatment Goals and Satisfaction at 1 Year in the Canadian Real-World APPRAISE Study
by: Vinod Chandran, et al.
Published: (2024-02-01) -
Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies
by: Peter Nash, et al.
Published: (2018-11-01)